Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

CD34+PBSC

Status:

Phase 2

Condition:

Systemic Sclerosis ILD

Intervention Type:

Intravenous (IV) Injection

Funder Type:

Organization | University

Drug Details

CD34+ positively selected peripheral blood stem cells (PBSC) is a high-dose immunoablative therapy.

Study Purpose

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect. We also hypothesize that our mechanistic studies will yield biomarkers that may herald disease recurrence or progression following alterations in the recovery of immune cells in the skin and/or bronchial lavage or blood.

Find a Clinical Trial